Genetic polymorphisms of NAMPT related with susceptibility to esophageal Squamous cell carcinoma

BMC Gastroenterology

Ziping Chen¹  Ruiping Hou¹  Meijuan Zhang¹  Changhong Liu¹  Tao Ning³  Wenjun Du¹  Changqing Xu¹  Shanshan Wang¹  Daojie Yan²  Chuanzhen Zhang¹ 

[1] Digestive Department, Shandong Provincial Qianfoshan Hospital, Shandong University, Jingshi Road 16766#, Jinan 250014, China;Infectious Diseases Hospital, Laiwu Hospital, Taishan Medical College, Laiwu, China;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Genetics, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China

关键词: Susceptibility;    Esophageal squamous cell carcinoma;    Haplotype;    Polymorphism;    Nicotinamide phosphoribosyl transferase;   

Others  :  1211539
DOI  :  10.1186/s12876-015-0282-6

 received in 2014-12-03, accepted in 2015-04-16,  发布年份 2015

【 摘 要 】

Background

Nicotinamide phosphoribosyl transferase (Nampt) plays a crucial role in tumorigenesis. The present study examines whether genetic polymorphisms of NAMPT are related to the risk of developing esophageal squamous cell carcinoma (ESCC).

Methods

A total of 810 subjects were enrolled in this study, including 405 ESCC patients and 405 healthy controls. Using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), genotypes at rs61330082, rs2505568 and rs9034 of NAMPT were identified. Haplotypes were constructed using PHASE software. Multivariate logistic regression models were used to evaluate the potentiating effects of the genotypes, alleles and haplotypes on the development of ESCC.

Results

The presence of genotypes CT and TT and allele T at rs61330082 was less frequent in ESCC cases than in controls (48.89% vs. 53.33%, P < 0.01, 95% CI: 0.33-0.68; 18.52% vs. 30.37%, P < 0.01, 95% CI: 0.22-0.50; 42.96% vs. 57.04%, P < 0.01, 95% CI: 0.38-0.61; respectively). No statistically significant differences existed in the distributions of genotypes or alleles at rs2505568 or rs9034 between ESCC cases and controls. Of five haplotypes constructed, haplotypes CTC, CTT and CAC were higher in ESCC cases (P < 0.01, OR = 1.57, 95% CI: 1.16-2.12; P = 0.04, OR = 1.72, 95% CI: 1.03-2.85; P < 0.01, OR = 3.39, 95% CI: 1.99-5.75; respectively) than in controls.

Conclusion

Genetic polymorphisms of NAMPT, specifically genotype CC and allele C at rs61330082 as well as haplotypes CTC, CTT and CAC, were significantly correlated with ESCC susceptibility.

【 授权许可】

   
2015 Zhang et al.; licensee BioMed Central.

【 参考文献 】

• [1]Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou HJ X: Esophageal cancer incidence and mortality in China, 2009. J Thoracic Dis 2013, 5:19-26.
• [3]Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14:1431-7.
• [4]Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al.: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-30.
• [5]Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D: Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer 2013, 4:447-56.
• [6]Ying W: NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 2008, 10:179-206.
• [7]Kim S, Bae S, Choi K, Park S, Jun HO, Lee J, et al.: Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007, 357:150-6.
• [8]Garten A, Petzold S, Körner A, Imai S, Kiess W: Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009, 20:130-8.
• [9]Housa D, Housová J, Vernerová Z, Haluzík M: Adipocytokines and cancer. Physiol Res 2006, 55:233-44.
• [10]Srivastava M, Khurana P, Sugadev R: Lung cancer signature biomarkers: tissue specific semantic similarity based clustering of digital differential display (DDD) data. BMC Res Notes 2012, 5:617. BioMed Central Full Text
• [11]Bi T, Che X: Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2014, 10:119-25.
• [12]Zhang K, Zhou B, Zhang P, Zhang Z, Chen P, Pu Y, et al.: Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. Tumor Biol 2014, 35:4031-40.
• [13]Blakemore AIF, Meyre D, Delplanque J, Vatin V, Lecoeur C, Marre M, et al.: A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity 2009, 17:1549-53.
• [14]O'Mahony DS, Glavan BJ, Holden TD, Fong C, Black RA, Rona G, et al.: Inflammation and immune-related candidate gene associations with acute lung injury susceptibility and severity: a validation study. PLoS One 2012., 7Article ID e51104
• [15]Nakajima TE, Yamada Y, Hamano T, Furuta K, Oda I, Kato H, et al.: Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 2010, 136:261-6.
• [16]Ghaemmaghami S, Mohaddes SM, Hedayati M, Gorgian MM, Dehbashi G: Resistin and visfatin expression in HCT-116 colorectal cancer cell line. Int J Mol Cell Med 2013, 2:143-50.
• [17]Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nüssler V, Hasmann M: Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006, 11:313-21.
• [18]Nakajima TE, Yamada Y, Hamano T, Furuta K, Oda I, Kato H, et al.: Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 2010, 136:261-6.